Clinical Trial

PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
PM8002 is a bispecific antibody targeting PD-L1 and VEGF. This study will evaluate the efficacy and safety of PM8002 in combination with Paclitaxel as second-line treatment for SCLC
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2024-09-25; most recent amendment 2026-05-19.
Status change: Recruiting → Active, Not Recruiting 2026-05-19
Status change: Not Yet Recruiting → Recruiting 2024-12-16
Trial Details
NCT Number NCT06616532
Lead Sponsor Biotheus Inc.
Conditions SCLC
Enrollment 404 participants
Start Date 2024-11-13
Primary Completion 2027-01-25 (estimated)
Study Completion 2028-12-25 (estimated)
Updated on ClinicalTrials.gov 2026-05-22